Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Syn-Ake vs Syn-Coll

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Syn-Ake and Syn-Coll share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer Syn-Ake has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Syn-Ake's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Syn-Ake

Cosmetic Clinical Studies

Syn-Coll

Cosmetic Clinical Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: minimal. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

Syn-Ake Syn-Coll
Class Cosmetic peptide (snake-venom inspired) Cosmetic lipopeptide (collagen)
Drug class Dermatologic Dermatologic
Mechanism Waglerin-1 mimic; antagonizes nicotinic ACh receptor at muscle TSP-1 mimic; activates latent TGF-β; stimulates collagen synthesis
Route Topical Topical
Half-life Topical Topical
Dosage (research) Topical 4% Topical 1-5%
Evidence tier Cosmetic Clinical Studies Cosmetic Clinical Studies
Research depth 5 indexed (PubMed 2 · CT 0 · EPMC 3) 12 indexed (PubMed 4 · CT 0 · EPMC 8)
Availability Cosmetic Cosmetic
Reported risks Minimal Minimal

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Syn-Ake or Syn-Coll?

Syn-Ake and Syn-Coll share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer Syn-Ake has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Syn-Ake's evidence base is currently denser.

What is the difference between Syn-Ake and Syn-Coll?

Syn-Ake is classed as Cosmetic peptide (snake-venom inspired); Syn-Coll is classed as Cosmetic lipopeptide (collagen). Reported mechanism: Syn-Ake, Waglerin-1 mimic; antagonizes nicotinic ACh receptor at muscle; Syn-Coll, TSP-1 mimic; activates latent TGF-β; stimulates collagen synthesis. Reported half-life: Syn-Ake, Topical; Syn-Coll, Topical. Routes in published studies: Syn-Ake, Topical; Syn-Coll, Topical.

Which has stronger evidence, Syn-Ake or Syn-Coll?

Syn-Ake and Syn-Coll sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Syn-Ake is graded Cosmetic Clinical Studies, with 3 cited sources on its reference page and 5 indexed studies. Syn-Coll is graded Cosmetic Clinical Studies, with 2 cited sources on its reference page and 12 indexed studies.

Which is more accessible, Syn-Ake or Syn-Coll?

Neither Syn-Ake nor Syn-Coll is an FDA-approved drug. Catalog status: Syn-Ake, Cosmetic; Syn-Coll, Cosmetic.

Are Syn-Ake and Syn-Coll ever combined?

Syn-Ake and Syn-Coll appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…